Reducing Salivary Toxicity with Adaptive Radiotherapy : A Randomized Controlled trial. - ReSTART

Tata Memorial Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Biopsy proven Squamous cell carcinoma of the oropharynx, hypopharynx and larynx.
•2.AJCC stage T1-3, N0-2c, M 0.
•3.KPS >= 70.
•4.Age >=18 and <= 70 years.
•5.Patient willing and reliable for follow-up.
•6.Patientâ??s nutritional & physical condition compatible with planned therapy.
•7.Signed study specific consent form.

•1.T1-2 N0 M0 of Vocal cords
•2.History of surgery for the primary or node in head and neck.
•3.Evidence of distant metastases or N3 nodal stage.
•4.Previous therapeutic irradiation for head & neck cancer.
•5.Patients who have received neoadjuvant chemotherapy.
•6.Active untreated infection, which preclude the use of systemic chemotherapy or would interfere with completion of treatment.
•7.Any histopathology other than Squamous Carcinoma.
•8.Primary nasopharyngeal or paranasal sinus cancers.
•9.Pregnancy or lactating women.
•10.Previous history of malignancy within 5 years.

发起方